Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (5,162,478)	$ (3,394,855)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	52,586	12,573
Warranty provision	18,909	3,503
Inventory write-off	(48,000)	(65,012)
Non-cash lease expense	59,800	22,211
Share-based compensation	1,016,235	600,898
Provision for doubtful accounts	10,140	0
Changes in assets and liabilities:
Accounts receivable	(306,979)	(26,863)
Inventories	206,036	(1,032,308)
Prepaid expenses and other current assets	(29,323)	(71,182)
Accounts payable	376,322	183,478
Operating lease liability	(62,369)	(20,893)
Customer deposits	(193,019)	0
Accrued liabilities and other	165,425	59,416
Deferred revenue	(200)	3,357
Net cash used in operating activities	(3,896,915)	(3,725,677)
Cash Flows From Investing Activities:
Capital expenditures for property and equipment	(68,584)	(108,616)
Investment in patents and trademarks	(82,003)	(68,501)
Long-term deposits	0	(11,169)
Net cash used in investing activities	(150,587)	(188,286)
Cash Flows From Financing Activities:
Sale of common stock and warrants	12,400,002	12,499,994
Offering costs paid on sale of common stock and warrants	(732,796)	(1,148,780)
Proceeds from exercise of warrants	10,250,532	1,557,285
Offering costs paid on exercise of warrants	(398,091)	0
Proceeds from exercise of stock options	514,875	24,375
Proceeds from bank note	414,362	0
Net cash provided by financing activities	22,448,884	12,932,874
Net decrease in cash and cash equivalents	18,401,382	9,018,911
Cash and cash equivalents, beginning of period	16,983,864	12,358,896
Cash and cash equivalents, end of period	35,385,246	21,377,807
Supplemental Disclosure of Non-Cash Investing and Financing Activities:
Right-of-use assets and liabilites recorded during period	0	341,000
Issuance costs relating to warrants issued to public offering selling agent	$ 0	$ 205,894